TMCnet News
Bovie Medical Receives FDA 510(k) Approval for Bovie Ultimate™ GeneratorBovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced that it has received FDA 510(k) approval for the Bovie Ultimate™ generator. The Bovie Ultimate™ is a high frequency electrosurgical generator that can be used for delivery of RF energy and/or helium gas plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The generator offers users monopolar, bipolar and plasma features, including one J-Plasma® helium gas outlet, in a single generator. Its pad-sensing system reduces the risk of patient burns, but this feature is not required when using helium gas mode for soft tissue coagulation. The Bovie Ultimate™ will replace Bovie's ICON™ GS plasma system. "We are pleased to have received FDA approval for this leading edge product, which combines J-Plasma® technology with the highest wattage operating room electrosurgical generator," said Robert L. Gershon, Chief Executive Officer. We designed the Bovie Ultimate™ to provide medical practitioners with greater flexibility, including the ability to easily incorporate our J-Plasma® product. This is an excellent illustration of our strategy to leverage synergies between our core product and J-Plasma® businesses to drive future revenue growth." The Company expects commercial launch of the new product in February, 2015. About Bovie Medical Corporation Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal thermal spread, and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company's own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie Medical Corporation's website www.boviemed.com. Cautionary Statement on Forward-Looking Statements Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Reports on Forms 10-K/A and 10-Qs for the year ended December 31, 2013 and the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
|
